Table 4 Characteristics of the 33 selected randomised controlled trials and the patients studied in them
From: A meta-analysis of the efficacy of fibromyalgia treatment according to level of care
N | Randomized controlled trial | Year | Country | Treatment | Level of care | % of women | Mean age | Length of treatment (years) | Simple size | Oxford scoring (quality) | Duration of disease at baseline (years) | Instruments used (outcome assessed) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Carette | 94 | Canada | Amitryptiline Cyclobenzaprine | Primary care | 93.8 | 44.4 | 24 | 208 | 3 | 7.7 | Mc Gill-BPI (p) SIP (gf) |
2 | Russell | 94 | USA | Malic acid | Specialised care | 90 | 49.5 | 8 | 24 | 3 | VAS (p) TPI (tp) | |
3 | Wolfe | 94 | USA | Fluoxetine | Primary care | 100 | 50.4 | 3 | 42 | 5 | 13 | TPI (tp) BDI (ad) |
4 | Carette | 95 | Canada | Amitryptiline | Primary care | 95.5 | 43.8 | 8 | 22 | 2 | 6.9 | VAS (p) VAS (i) VAS (gf) |
5 | Chesky | 95 | USA | Music vibration | Specialised care | 92.6 | 48.8 | 30 minutes | 26 | 3 | 11 | VAS (p) TPI (tp) |
6 | Goldenberg | 96 | USA | Fluoxetine Amitryptiline | Primary care | 90.3 | 43 | 6 | 31 | 5 | 5.7 | VAS (p) FIQ (GF) BDI (ad) VAS (i) VAS (gf) VAS (f) TPI (tp) |
7 | Ginsberg | 96 | Belgium | Amitryptiline | Primary care | 82.5 | 46 | 8 | 46 | 2 | 32 | VAS (p) VAS (i) TPI (tp) VAS (f) VAS (gf) NTP (tp) |
8 | Moldofsky | 96 | Canada | Zolpidem | Primary care | 95 | 42 | 2.5 | 19 | 4 | NTP (tp) PGI (i) | |
9 | Vlayen | 96 | Holland | Cognitive behavioural therapy Education training | Specialised care | 87 | 44 | 6 | 131 | 5 | 10 | BDI (ad) |
10 | Wigers | 96 | Norway | Aerobic exercise Stress-reduction treatment | Specialised care | 92 | 44 | 14 | 48 | 3 | 10 | VAS (p) VAS (i) VAS (f) |
11 | Pearl | 96 | Canada | Bright light treatment | Specialised care | 100 | 38 | 10 | 14 | 2 | 5 | VAS (p) VAS (f) VAS (i) |
12 | Kelli | 97 | Canada | Chiropractic treatment | Specialised care | - | 49 | 4 | 19 | 4 | 8 | VAS (p) NTP (tp) |
13 | Hannonen | 98 | Finland | Moclobemide Amitryptiline | Primary care | 100 | 49 | 12 | 130 | 5 | 11.2 | NTP (tp) VAS (p) VAS (f) VAS (i) |
14 | Yavuzer | 98 | Turkey | Moclobemide | Primary care | 58 | 33 | 6 | 60 | 1 | TPI (tp) | |
15 | Ginsberg | 98 | Belgium | Pirlindole | Specialised care | 85 | 40 | 4 | 61 | 4 | 2.9 | VAS (p) TPI (tp) VAS (gf) |
16 | Russell | 00 | USA | Tramadol | Primary care | 94 | 49 | 6 | 69 | 4 | 4.7 | VAS (p) FIQ (gf) NTP (tp) |
17 | Heymann | 01 | Brazil | Amitryptiline Nortryptiline | Primary care | 100 | 50 | 8 | 118 | 4 | FIQ (gf) NTP (tp) | |
18 | Färber | 01 | Germany | Tropisetron | Specialised care | 92 | 48 | 1.5 | 403 | 3 | 11 | Vas (p) NTP (tp) |
19 | Gowans | 01 | Canada | Exercise | Specialised care | 88 | 47 | 23 | 50 | 3 | 9 | FIQ (gf) BDI (ad) STAI (ad) NTP (tp) |
20 | Mannerkorpi | 01 | Sweden | Education training | Specialised care | 100 | 46 | 24 | 58 | 4 | 8.7 | FIQ (gf) QOLS (ql) |
21 | Gür | 02 | Turkey | Laser Amitryptiline | Primary care (Amytriptiline) – Specialised care (laser) | 80 | 30 | 8 | 75 | 3 | 4.6 | HADS (ad) FIQ (gf) |
22 | Joaquim | 02 | Sweden | Education training Behavioural therapy | Specialised care | 100 | 45 | 12 | 53 | 6 | 3.6 pain | FIQ (gf) Mc Gill (p) |
23 | King | 02 | Canada | Exercise Education training | Specialised care | 100 | 46 | 12 | 152 | 4 | FIQ (gf) NTP (tp) | |
24 | Lemstra | 05 | Canada | Rehabilitation | Specialised care | 84.5 | 49.5 | 6 | 79 | 3 | 10 | VAS (p) BDI (ad) |
25 | Schachter | 03 | Canada | Aerobic exercise (long-term and short-term) | Specialised care | 100 | 42 | 16 | 143 | 4 | 3.5 | VAS (p) FIQ (gf) |
26 | Arnold | 04 | USA | Duloxetine | Primary care | 88 | 49 | 12 | 207 | 6 | 8.9 | BDI (ad) BPI (ad) NTP (tp) CGI (gf) FIQ (gf) |
27 | Yildiz | 04 | Turkey | Hyperbaric oxigen therapy | Specialised care | 70 | 40 | 2.5 | 50 | 2 | 4.5 | VAS (p) NTP (tp) |
28 | Crofford | 05 | USA | Pregabaline | Primary care | 92 | 48.5 | 8 | 529 | 5 | 9 | VAS (p) MAF (f) |
29 | Arnold | 05 | USA | Duloxetine | Primary care | 100 | 50 | 12 | 354 | 5 | BPI (ad) | |
30 | Gendreau | 05 | USA | Milnacipran | Primary care | 98 | 47 | 12 | 125 | 6 | 4.1 | FIQ (gf) |
31 | Finckh | 05 | Switzerland | Dehydroepiandrosterone (DHA) | Specialised care | 100 | 59 | 12 | 52 | 6 | 13 | HADS (ad) VAS (f) |
32 | Holman | 05 | USA | Pramipexole | Specialised care | 94.4 | 48.5 | 14 | 60 | 6 | 8.4 | BDI (ad) HAMD (ad) TPI (tp) FIQ (gf) |
33 | Edinger | 05 | USA | Cognitive behavioural therapy Sleep hygiene | Specialised care | 100 | 49 | 6 | 47 | 3 | Mc Gill (p) BPI (ad) SF-36 (ql) |